Phibro Animal Health (PAHC)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
$35.40-10.22%
Close 2026-11-05 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
QuarterlyIQ Insights · PAHC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 15.6% |
| Our one-year growth estimate | diamond | 3.5% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 12.1 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 11 industry peers · Company calendar date is not available
PAHC — earnings in line
Dated 2026-11-04
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On November 4, 2026, Phibro Animal Health Corporation issued a press release announcing its operating results for the fiscal quarter ended September 30, 2026 and its financial guidance for the fiscal year ending June 30, 2027. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this report, including the exhibit attached hereto, is being furnished and shall not be deemed to be…
Why it matters: Phibro plans to stop production at the site in summer 2027 and move products elsewhere. Delays or lost output could hurt sales and margins.
Watch forPhibro reports that production shifts to other sites and contract makers on schedule. No major supply problems occur.
Also watch forPhibro reports a delay, lost output, or customer supply problems tied to the site closure.
Why it matters: June-quarter gross margin rose, but Phibro also reported higher input costs and employee costs. EBITDA shows whether sales gains offset them.
Watch forQuarterly adjusted EBITDA grows from a year earlier. The company keeps its $258–$268 million fiscal 2027 range.
Also watch forQuarterly adjusted EBITDA falls year over year or Phibro cuts its fiscal 2027 range.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$143 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $446 loss on $10,000 · 4.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,231 loss on $10,000 · 52.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.